Thromboinflammation in therapeutic medicine

Advances in Experimental Medicine and Biology

Volumn 865, Issue , 2015, Pages 3-17

  Ekdahl, Kristina N ^a   Teramura, Yuji ^b   Asif, Sana ^c   Jonsson, Nina ^c,d   Magnusson, Peetra U ^c   Nilsson, Bo ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF TOKYO   (Japan)

^c UPPSALA UNIVERSITY   (Sweden)

^d LINNAEUS UNIVERSITY   (Sweden)

Author keywords

Coagulation; Complement; Extracorporeal treatment; Platelets; Therapeutic medicine; Thromboinflammation

Indexed keywords

ADENOSINE DIPHOSPHATE; BIOMATERIAL; BLOOD CLOTTING FACTOR 12; COMPLEMENT; HIGH MOLECULAR WEIGHT KININOGEN; KALLIKREIN; PEG CONJUGATED PHOSPHOLIPID; POLYMER; PREKALLIKREIN; REGULATOR OF COMPLEMENT ACTIVATION CAPTURING PEPTIDE; UNCLASSIFIED DRUG; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR; IMMUNOLOGIC FACTOR;

ANTIGEN RECOGNITION; ARTICLE; AUTOREGULATION; BIOCOMPATIBILITY; BLOOD CLOTTING; BLOOD COMPATIBILITY; CARDIOPULMONARY BYPASS; CELL ACTIVATION; CELL INTERACTION; CELL TRANSPLANTATION; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; DRUG DELIVERY DEVICE; ENDOTHELIUM; EXTRACORPOREAL OXYGENATION; HUMAN; INFLAMMATION; INNATE IMMUNITY; ISCHEMIA; LEUKOCYTE; MATERIAL COATING; MOLECULAR INTERACTION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEPLETION; REPERFUSION INJURY; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOCYTE; THROMBOINFLAMMATION; THROMBOSIS; TISSUE INJURY; CYTOLOGY; DRUG EFFECTS; ENDOTHELIUM CELL; GRAFT REJECTION; HUMORAL IMMUNITY; IMMUNOLOGY; METABOLISM; PATHOLOGY; TISSUE TRANSPLANTATION;

ANTICOAGULANTS; BIOCOMPATIBLE MATERIALS; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; BLOOD PLATELETS; COMPLEMENT SYSTEM PROTEINS; ENDOTHELIAL CELLS; GRAFT REJECTION; HUMANS; IMMUNITY, HUMORAL; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; INFLAMMATION; LEUKOCYTES; THROMBOSIS; TISSUE TRANSPLANTATION;

EID: 84940366281     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-319-18603-0_1     Document Type: Article

References (70)

1. Nilsson B, Korsgren O, Lambris JD, Ekdahl KN. Can cells and biomaterials in therapeutic medicine be shielded from innate immune recognition? Trends Immunol. 2010;31:32-8.
2. Nilsson B, Larsson R, Hong J, Elgue G, Ekdahl KN, Sahu A, et al. Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation. Blood. 1998;92:1661-7.
3. Markiewski MM, Nilsson B, Ekdahl KN, Mollnes TE, Lambris JD. Complement and coagulation: strangers or partners in crime? Trends Immunol. 2007;28:184-92.
4. Choi EY, Chavakis E, Czabanka MA, Langer HF, Fraemohs L, Economopoulou M, et al. Del-1, an endogenous leukocyte-endothelial adhesion inhibitor, limits inflammatory cell recruitment. Science. 2008;322:1101-4.
5. Croix DA, Ahearn JM, Rosengard AM, Han S, Kelsoe G, Ma M, et al. Antibody response to a T-dependent antigen requires B cell expression of complement receptors. J Exp Med. 1996;183:1857-64.
6. Nilsson B, Ekdahl KN, Mollnes TE, Lambris JD. The role of complement in biomaterialinduced inflammation. Mol Immunol. 2007;44:82-94.
7. Isermann B, Vinnikov IA, Madhusudhan T, Herzog S, Kashif M, Blautzik J, et al. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med. 2007;13:1349-58.
8. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11:785-97.
9. Bäck J, Huber-Lang M, Elgue G, Kalbitz M, Sanchez J, Ekdahl KN, et al. Distinctive regulation of contact activation by antithrombin and C1-inhibitor on activated platelets and material surfaces. Biomaterials. 2009;30:6573-80.
10. Bäck J, Sanchez J, Elgue G, Ekdahl KN, Nilsson B. Activated human platelets induce factor XIIa-mediated contact activation. Biochem Biophys Res Commun. 2010;391:11-7.
11. Bäck J, Lood C, Bengtsson AA, Ekdahl KN, Nilsson B. Contact activation products are new potential biomarkers to evaluate the risk of thrombotic events in systemic lupus erythematosus. Arthritis Res Ther. 2013;15:R206.
12. Hamad OA, Ekdahl KN, Nilsson PH, Andersson J, Magotti P, Lambris JD, et al. Complement activation triggered by chondroitin sulfate released by thrombin receptor-activated platelets. J Thromb Haemost. 2008;6:1413-21.
13. Hamad OA, Nilsson PH, Lasaosa M, Ricklin D, Lambris JD, Nilsson B, et al. Contribution of chondroitin sulfate A to the binding of complement proteins to activated platelets. PLoS One. 2010;5:12889.
14. Hamad OA, Nilsson PH, Wouters D, Lambris JD, Ekdahl KN, Nilsson B. Complement component C3 binds to activated normal platelets without preceding proteolytic activation and promotes binding to complement receptor 1. J Immunol. 2010;84:2686-92.
15. Hamad OA, Bäck J, Nilsson PH, Nilsson B, Ekdahl KN. Platelets, complement, and contact activation: partners in inflammation and thrombosis. Adv Exp Med Biol. 2012;946:185-205.
16. Kolářová H, Ambrůzová B, Svihálková Šindlerová L, Klinke A, Kubala L. Modulation of endothelial glycocalyx structure under inflammatory conditions. Mediators Inflamm. 2014;2014:694312.
17. Yang G, Lucas R, Caldwell R, Yao L, Romero MJ, Caldwell RW. Novel mechanisms of endothelial dysfunction in diabetes. J Cardiovasc Dis Res. 2010;1:59-63.
18. van Golen RF, van Gulik TM, Heger M. Mechanistic overview of reactive species-induced degradation of the endothelial glycocalyx during hepatic ischemia/reperfusion injury. Free Radic Biol Med. 2012;52:1382-402.
19. Singh A, Ramnath RD, Foster RR, Wylie EC, Friden V, Dasgupta I, et al. Reactive oxygen species modulate the barrier function of the human glomerular endothelial glycocalyx. PLoS One. 2013;8, e55852.
20. Hajishengallis G, Chavakis T. Endogenous modulators of inflammatory cell recruitment. Trends Immunol. 2013;34:1-6.
21. Langer HF, Chavakis T. Leukocyte-endothelial interactions in inflammation. J Cell Mol Med. 2009;13:1211-20.
22. Huo Y, Schober A, Forlow SB, Smith DF, Hyman MC, Jung S, et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med. 2003;9:61-7.
23. Simon DI, Chen Z, Xu H, Li CQ, Dong J, McIntire LV, et al. Platelet glycoprotein ibalpha is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J Exp Med. 2000;192: 193-204.
24. Santoso S, Sachs UJ, Kroll H, Linder M, Ruf A, Preissner KT, et al. The junctional adhesion molecule 3 (JAM-3) on human platelets is a counterreceptor for the leukocyte integrin Mac-1. J Exp Med. 2002;196:679-91.
25. Chavakis T, Santoso S, Clemetson KJ, Sachs UJ, Isordia-Salas I, Pixley RA, et al. High molecular weight kininogen regulates platelet-leukocyte interactions by bridging Mac-1 and glycoprotein Ib. J Biol Chem. 2003;278:45375-81.
26. Langer HF, Choi EY, Zhou H, Schleicher R, Chung KJ, Tang Z, et al. Platelets contribute to the pathogenesis of experimental autoimmune encephalomyelitis. Circ Res. 2012;110:1202-10.
27. Wang Y, Sakuma M, Chen Z, Ustinov V, Shi C, Croce K, et al. Leukocyte engagement of platelet glycoprotein Ibalpha via the integrin Mac-1 is critical for the biological response to vascular injury. Circulation. 2005;112:2993-3000.
28. Simon DI. Inflammation and vascular injury: basic discovery to drug development. Circ J. 2012;76:1811-8.
29. Engberg AE, Rosengren-Holmberg JP, Chen H, Nilsson B, Lambris JD, Nicholls IA, et al. Blood protein-polymer adsorption: implications for understanding complement-mediated hemoincompatibility. J Biomed Mater Res A. 2011;97:74-84.
30. Engberg AE, Nilsson PH, Huang S, Fromell K, Hamad OA, Mollnes TE, et al. Prediction of inflammatory responses induced by biomaterials in contact with human blood using protein fingerprint from plasma. Biomaterials. 2015;36:55-65.
31. Ekdahl KN, Lambris JD, Elwing H, Ricklin D, Nilsson PH, Teramura Y, et al. Innate immunity activation on biomaterial surfaces: a mechanistic model and coping strategies. Adv Drug Deliv Rev. 2011;63:1042-50.
32. Vazquez MA. Vascular access for dialysis: recent lessons and new insights. Curr Opin Nephrol Hypertens. 2009;18:116-21.
33. Cavalli A, Del Vecchio L, Manzoni C, Locatelli F. Hemodialysis: yesterday, today and tomorrow. Minerva Urol Nefrol. 2010;62:1-11.
34. Kourtzelis I, Markiewski MM, Doumas M, Rafail S, Kambas K, Mitroulis I, et al. Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis. Blood. 2010;116:631-9.
35. Qu H, Magotti P, Ricklin D, Wu EL, Kourtzelis I, Wu YQ, et al. Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potency. Mol Immunol. 2011;48:481-9.
36. Gustafson EK, Elgue G, Hughes RD, Mitry RR, Sanchez J, Haglund U, et al. The instant blood-mediated inflammatory reaction characterized in hepatocyte transplantation. Transplantation. 2011;91:632-8.
37. Moll G, Jitschin R, von Bahr L, Rasmusson-Duprez I, Sundberg B, Lonnies L, et al. Mesenchymal stromal cells engage complement and complement receptor bearing innate effector cells to modulate immune responses. PLoS One. 2011;6, e21703.
38. Moll G, Rasmusson-Duprez I, von Bahr L, Connolly-Andersen AM, Elgue G, Funke L, et al. Are therapeutic human mesenchymal stromal cells compatible with human blood? Stem Cells. 2012;30:1565-74.
39. Moberg L, Johansson H, Lukinius A, Berne C, Foss A, Kallen R, et al. Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet. 2002;360:2039-45.
40. Johansson H, Lukinius A, Moberg L, Lundgren T, Berne C, Foss A, et al. Tissue factor produced by the endocrine cells of the islets of Langerhans is associated with a negative outcome of clinical islet transplantation. Diabetes. 2005;54:1755-62.
41. Goto M, Tjernberg J, Dufrane D, Elgue G, Brandhorst D, Ekdahl KN, et al. Dissecting the instant blood-mediated inflammatory reaction in islet xenotransplantation. Xenotransplantation. 2008;15:225-34.
42. van der Windt DJ, Bottino R, Casu A, Campanile N, Cooper DK. Rapid loss of intraportally transplanted islets: an overview of pathophysiology and preventive strategies. Xenotransplantation. 2007;14:288-97.
43. Nilsson B, Ekdahl KN, Korsgren O. Control of instant blood-mediated inflammatory reaction to improve islets of Langerhans engraftment. Curr Opin Organ Transplant. 2011;16:620-6.
44. Nilsson B, Teramura Y, Ekdahl KN. The role and regulation of complement activation as part of the thromboinflammation elicited in cell therapies. Mol Immunol. 2014;61:185-90.
45. Eltzschig HK, Eckle T. Ischemia and reperfusion-from mechanism to translation. Nat Med. 2011;17:1391-401.
46. Lappegard KT, Bergseth G, Riesenfeld J, Pharo A, Magotti P, Lambris JD, et al. The artificial surface-induced whole blood inflammatory reaction revealed by increases in a series of chemokines and growth factors is largely complement dependent. J Biomed Mater Res A. 2008;87:129-35.
47. Yang W, Bai T, Carr LR, Keefe AJ, Xu J, Xue H, et al. The effect of lightly crosslinked poly(carboxybetaine) hydrogel coating on the performance of sensors in whole blood. Biomaterials. 2012;33:7945-51.
48. Chien HW, Tsai WB, Jiang S. Direct cell encapsulation in biodegradable and functionalizable carboxybetaine hydrogels. Biomaterials. 2012;33:5706-12.
49. Leijon J, Carlsson F, Brännström J, Sanchez J, Larsson R, Nilsson B, et al. Attachment of flexible heparin chains to gelatin scaffolds improves endothelial cell infiltration. Tissue Eng Part A. 2013;19:1336-48.
50. Richter AW, Akerblom E. Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors. Int Arch Allergy Appl Immunol. 1984;74:36-9.
51. Andersson J, Larsson R, Richter R, Ekdahl KN, Nilsson B. Binding of a model regulator of complement activation (RCA) to a biomaterial surface: surface-bound factor H inhibits complement activation. Biomaterials. 2001;22:2435-43.
52. Andersson J, Bexborn F, Klinth J, Nilsson B, Ekdahl KN. Surface-attached PEO in the form of activated Pluronic with immobilized factor H reduces both coagulation and complement activation in a whole-blood model. J Biomed Mater Res A. 2006;76:25-34.
53. Watkins NJ, Braidley P, Bray CJ, Savill CM, White DJ. Coating of human decay accelerating factor (hDAF) onto medical devices to improve biocompatibility. Immunopharmacology. 1997;38:111-8.
54. Wu YQ, Chen H, Ricklin D, Nilsson B, Ekdahl KN, Lambris JD. Protection of non-self surfaces from complement attack by factor H-binding peptides: implications for therapeutic medicine. J Immunol. 2011;186:4269-77.
55. Engberg AE, Sandholm K, Bexborn F, Persson J, Nilsson B, Lindahl G, et al. Inhibition of complement activation on a model biomaterial surface by streptococcal M protein-derived peptides. Biomaterials. 2009;30:2653-9.
56. Jin RC, Voetsch B, Loscalzo J. Endogenous mechanisms of inhibition of platelet function. Microcirculation. 2005;12:247-58.
57. Eltzschig HK, Thompson LF, Karhausen J, Cotta RJ, Ibla JC, Robson SC, et al. Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: coordination by extracellular nucleotide metabolism. Blood. 2004;104:3986-92.
58. Reutershan J, Cagnina RE, Chang D, Linden J, Ley K. Therapeutic anti-inflammatory effects of myeloid cell adenosine receptor A2a stimulation in lipopolysaccharide-induced lung injury. J Immunol. 2007;179:1254-63.
59. Roberts V, Lu B, Rajakumar S, Cowan PJ, Dwyer KM. The CD39-adenosinergic axis in the pathogenesis of renal ischemia-reperfusion injury. Purinergic Signal. 2013;9:135-43.
60. Eltzschig HK, Ibla JC, Furuta GT, Leonard MO, Jacobson KA, Enjyoji K, et al. Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors. J Exp Med. 2003;189:783-96.
61. Buergler JM, Maliszewski CR, Broekman MJ, Kaluza GL, Schulz DG, Marcus AJ, et al. Effects of SolCD39, a novel inhibitor of Platelet Aggregation, on Platelet Deposition and Aggregation after PTCA in a Porcine Model. J Thromb Thrombolysis. 2005;19:115-22.
62. Cai M, Huttinger ZM, He H, Zhang W, Li F, Goodman LA, et al. Transgenic over expression of ectonucleotide triphosphate diphosphohydrolase-1 protects against murine myocardial ischemic injury. J Mol Cell Cardiol. 2011;51:927-35.
63. Dwyer KM, Robson SC, Nandurkar HH, Campbell DJ, Gock H, Murray-Segal LJ, et al. Thromboregulatory manifestations in human CD39 transgenic mice and the implications for thrombotic disease and transplantation. J Clin Invest. 2004;113:1440-6.
64. Crikis S, Lu B, Murray-Segal LM, Selan C, Robson SC, D'Apice AJ, et al. Transgenic overexpression of CD39 protects against renal ischemia-reperfusion and transplant vascular injury. Am J Transplant. 2010;10:2586-95.
65. Nilsson PH, Engberg AE, Bäck J, Faxälv L, Lindahl TL, Nilsson B, et al. The creation of an antithrombotic surface by apyrase immobilization. Biomaterials. 2010;31:4484-91.
66. Nilsson PH, Ekdahl KN, Magnusson PU, Qu H, Iwata H, Ricklin D, et al. Autoregulation of thromboinflammation on biomaterial surfaces by a multicomponent therapeutic coating. Biomaterials. 2012;34:985-94.
67. Teramura Y, Iwata H. Surface modification of islets with PEG-lipid for improvement of graft survival in intraportal transplantation. Transplantation. 2009;88:624-30.
68. Teramura Y, Iwata H. Improvement of graft survival by surface modification with poly(ethylene glycol)-lipid and urokinase in intraportal islet transplantation. Transplantation. 2011;91:271-8.
69. Teramura Y, Minh LN, Kawamoto T, Iwata H. Microencapsulation of islets with living cells using PolyDNA-PEG-lipid conjugate. Bioconjugate Chem. 2010;21:792-6.
70. Teramura Y, Oommen OP, Olerud J, Hilborn J, Nilsson B. Microencapsulation of cells, including islets, within stable ultra-thin membranes of maleimide-conjugated PEG-lipid with multifunctional crosslinkers. Biomaterials. 2013;34:2683-93.